SavePeptides
SavePeptidesCompound
Re-checked hourly
All peptides
GrowthFDA-approvedVendors pending
FDA-approvedVendors pendingFacts verified · 2026-05-25

Tesamorelin + Ipamorelin

Also known as ghrh(1–44) analog + ipamorelin, 2x blend tesamorelin, tesamorelin +ipamorelin, tesamorelin (11mg) + ipamorelin (3mg) blend

Tesamorelin + Ipamorelin is a compounded research-chemical blend pairing a stabilized GHRH(1-44) analog (tesamorelin, FDA-approved as monotherapy for HIV-associated lipodystrophy under the brand Egrifta) with the selective ghrelin/GHS-R1a agonist ipamorelin. The combination is positioned for GH/IGF-1 support, visceral fat reduction, recovery, and sleep quality, and is typically marketed as a 10-11 mg tesamorelin / 2-3 mg ipamorelin per vial blend. No controlled human trials of the blend itself exist; supporting evidence comes from monotherapy studies of each component. Also known as GHRH(1-44) analog + Ipamorelin.

—

best

price

—

per

mg

—

vendors

tracked

FDA-approved

stage

Formulation note

Tesamorelin (GHRH analog, FDA-approved monotherapy) + Ipamorelin (selective ghrelin agonist). The blend itself is not FDA-approved.

What's in this blend

2 components.

Growth

Tesamorelin

Tesamorelin (TH9507; Egrifta SV; Egrifta WR) is a stabilized synthetic analogue of human growth hormone-releasing hormone GHRH(1-44) developed by Theratechnologies.

Growth

Ipamorelin

Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) classified as a selective ghrelin/GHSR1a receptor agonist.

Vendor data

Coming soon.

Per-vendor pricing and verification tiers populate as the SavePeptides crawler comes online. Until then, browse all approved vendors directly.

Browse all vendors

Mechanism of action

The blend combines two complementary growth-hormone secretagogues. Tesamorelin is a stabilized GHRH(1-44) analog that binds the pituitary GHRH receptor to amplify endogenous GH pulse amplitude and uniquely reduces visceral adipose tissue (VAT) in HIV-associated lipodystrophy by roughly 11-18% across phase 3 trials (https://pubmed.

The blend combines two complementary growth-hormone secretagogues. Tesamorelin is a stabilized GHRH(1-44) analog that binds the pituitary GHRH receptor to amplify endogenous GH pulse amplitude and uniquely reduces visceral adipose tissue (VAT) in HIV-associated lipodystrophy by roughly 11-18% across phase 3 trials (https://pubmed.ncbi.nlm.nih.gov/20101189/ ; https://pubmed.ncbi.nlm.nih.gov/22050344/). Ipamorelin is a pentapeptide agonist of the growth hormone secretagogue receptor GHS-R1a (the ghrelin receptor) that recruits additional somatotrophs and suppresses somatostatin tone, increasing GH release without measurable rises in cortisol or prolactin (https://pubmed.ncbi.nlm.nih.gov/12168778/). Concurrent activation of GHRH and ghrelin pathways is synergistic in monotherapy studies of GHRH+GHS combinations, but the specific tesamorelin/ipamorelin blend has not been formally tested in humans.

Pharmacokinetic properties

Half-life

Tesamorelin ~26-38 min; ipamorelin ~2 h (both SC)

Routes

subcutaneous

Bioavailability

Both components short-acting; blend typically dosed once daily SC, often at bedtime to align with natural GH pulse.

Amino-acid sequence

(GHRH 1-44 analog) + Aib-His-D-2-Nal-D-Phe-Lys-NH2

Use & research dosing

GH/IGF-1 SupportVisceral Fat ReductionGH ReleaseRecoverySleep Quality

No FDA-approved formulation of this blend exists; tesamorelin alone is FDA-approved at 2 mg SC daily for HIV lipodystrophy. In self-experimentation reports, blends are typically dosed once daily SC at bedtime to align with natural GH pulses, with users titrating a reconstituted 10 mg tes / 2 mg ipa vial to deliver roughly 1 mg tesamorelin + 200 mcg ipamorelin per injection. Cycle lengths of 8-16 weeks are most commonly described. Research framing only.

Research-use framing only. SavePeptides sells nothing for human consumption. Doses above reflect reported research / self-experimentation ranges, not clinical recommendations.

Editorial perspective

Marketed as a more potent visceral-fat-targeting alternative to CJC-1295/ipamorelin blends, leveraging tesamorelin's documented VAT-reducing effect in HIV lipodystrophy. Per-mg cost is materially higher than CJC/ipamorelin blends. Important caveat: no peer-reviewed human study of this specific combination has been published; all efficacy claims are inferred from monotherapy data on each component.

— SavePeptides editorial desk · last updated 2026-05-25

Cautions & contraindications

Before researching this compound, note:

  • Blend is not FDA- or EMA-approved; only tesamorelin monotherapy is approved (HIV-associated lipodystrophy)
  • No controlled human trials of the combination - efficacy and safety are extrapolated from component data
  • Avoid in active or suspected malignancy (GH/IGF-1 axis activation)
  • Avoid in pregnancy and breastfeeding
  • May cause glucose intolerance, insulin resistance, or worsen pre-existing diabetes
  • Fluid retention, arthralgia, peripheral edema, carpal-tunnel-like symptoms
  • Injection site reactions (erythema, pruritus, induration) are common with tesamorelin
  • Avoid in patients with disrupted hypothalamic-pituitary axis or active pituitary disease
  • Long-term safety data lacking for the blend; class caution for chronic supraphysiologic GH exposure

Research foundation

The papers behind the page.

  1. [01]https://pubmed.ncbi.nlm.nih.gov/20101189/
  2. [02]https://pubmed.ncbi.nlm.nih.gov/22050344/
  3. [03]https://pubmed.ncbi.nlm.nih.gov/22298602/
  4. [04]https://pubmed.ncbi.nlm.nih.gov/12168778/
  5. [05]https://pmc.ncbi.nlm.nih.gov/articles/PMC9947601/

Facts verified

2026-05-25

Confidence

low

What this means

  • no human trials of the combined blend
  • efficacy extrapolated from monotherapy data on each component

How we check →

Vendor data coming soon

All vendors

001 — Independent

We don't list what we wouldn't research.

SavePeptides lists vendors after an initial review and distinguishes verified vendors where additional checks have been completed. We may earn commissions from referral links, and sponsored placements will be clearly disclosed.

002 — Vendor-funded

Free to browse. Supported by referrals.

SavePeptides is free for buyers. We may earn a commission when you order through our links, but we do not lock deals behind a paywall, require an email to view codes, or inflate comparison prices.

003 — Research use

Research-use disclaimer.

SavePeptides surfaces vendor, pricing, and coupon information for research compounds. These products are not intended, approved, or recommended for human consumption. Our content is informational only and does not constitute medical advice.